Navigation Links
Transition Therapeutics Announces Dates for Upcoming Corporate Events
Date:12/1/2008

TORONTO, Dec. 1 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH, NASDAQ: TTHI) today announced the dates for the following upcoming corporate events:

20th Annual Piper Jaffray Health Care Conference

Transition will present at the upcoming 20th Annual Piper Jaffray Health Care Conference. The presentation will take place on Tuesday, December 2nd, 2008 at 12:30 P.M. (Eastern Time) at the New York Palace.

2008 Annual General Meeting of Shareholders

Transition's Annual General Meeting will occur Monday, December 8, 2008 at the MaRS Centre, South Tower, 101 College Street, Main Floor, Room CR-3, Toronto, Ontario at 4:00 P.M. (Eastern Time).

2008 Healthcare Conference hosted by RBC Capital Markets

Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition, will participate in the upcoming 2008 Healthcare Conference hosted by RBC Capital Markets. Dr. Cruz is scheduled to participate in a panel session titled "The Challenge of Alzheimer's Disease" on Thursday, December 11th, 2008 between 12:30 - 1:25 P.M. (Eastern Time) at the Westin Times Square New York. A live webcast and archived version of this event will be available on the Transition website www.transitiontherapeutics.com.

    About Transition
    ----------------

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.


'/>"/>
SOURCE Transition Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
2. Respiratory Leaders Urge Medical Community to Educate Patients Transitioning CFC to HFA Inhalers
3. Transitions Optical to Provide Free Vision Screenings at the American Diabetes Associations Feria de Salud por tu Familia(TM)
4. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
5. Schering-Plough Announces Transition of Animal Health Leadership
6. ACS Signs $27 Million Contract with Alaska to Transition Fiscal Agent Services for State Medicaid Program
7. MidSouth eHealth Alliance to Transition to Commercial Software Solution from Informatics Corporation of America
8. Transition Therapeutics Announces No Material Change
9. Transitions Optical Offers Tips on How to Protect Eyes for Outdoor Sports Fans
10. Transition Therapeutics Announces Executive Management Appointments
11. AGA Medical Announces Management Transition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) aired ... of 2016. The program was made possible by a Pennsylvania Department of Health ... and Human Services Administration. The broadcast, Use Your Head: Properly Managing Sport ...
(Date:12/8/2016)... Islandia, NY (PRWEB) , ... December 08, 2016 ... ... company, is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture ... published in JMIR Medical Informatics . , Results of the comparative usability ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Center has been recognized for adherence to the highest standards of trauma, ... accreditation organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among ...
(Date:12/8/2016)... ... 2016 , ... Vida Health, the digital health platform that pairs ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor Aspect ... consumers who are managing chronic conditions or simply want to improve their ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... poised to grow in 2017-2023. Various reasons for growth ... obese population, higher incidences of chronic diseases, high recovery ... mobility aid services. Medical lifting sling refers to ... with limited mobility. These slings connect to the lift ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
Breaking Medicine Technology: